No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.

Paul, Stephane; Williet, Nicolas; Nancey, Stéphane; Veyrard, Pauline; Boschetti, Gilles; Phelip, Jean-Marc; Flourie, Bernard; Roblin, Xavier

No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.

Paul, Stephane; Williet, Nicolas; Nancey, Stéphane; Veyrard, Pauline; Boschetti, Gilles; Phelip, Jean-Marc; Flourie, Bernard; Roblin, Xavier.

Afiliación

Paul S; Faculty of Medicine of Saint-Etienne, Immunology Unit University hospital of saint Etienne, CIC INSERM 1408, Saint-Etienne, France.
Williet N; Groupe Immunité des muqueuses et Agents Pathogènes (GIMAP), INSERM U1111- International center for research in infectiology (CIRI), Saint-Etienne, France.
Nancey S; Department of Gastroenterology, Saint-Etienne University hospital, Saint-Etienne, France.
Veyrard P; Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France.
Boschetti G; University Claude Bernard Lyon 1, Lyon, France.
Phelip JM; INSERM U1111- International center for research in infectiology (CIRI), Lyon, France.
Flourie B; Department of Gastroenterology, Saint-Etienne University hospital, Saint-Etienne, France.
Roblin X; Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France.

Dig Dis Sci ; 66(8): 2744-2749, 2021 08.

Article en En | MEDLINE | ID: mdl-32936345

Asunto(s)

Adalimumab/farmacocinética; Antiinflamatorios/farmacocinética; Enfermedades Inflamatorias del Intestino/tratamiento farmacológico; Adalimumab/administración & dosificación; Adalimumab/uso terapéutico; Adulto; Antiinflamatorios/administración & dosificación; Antiinflamatorios/uso terapéutico; Anticuerpos/sangre; Área Bajo la Curva; Estudios de Cohortes; Relación Dosis-Respuesta a Droga; Femenino; Humanos; Masculino; Persona de Mediana Edad; Adulto Joven

Palabras clave

Adalimumab; Anti-adalimumab antibodies; Pharmacokinetics; Switch

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Adalimumab / Antiinflamatorios Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Dig Dis Sci Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google